NZ543111A - Method and use for the reversible aggregation and/or dissociation of polypeptides (comprising peptide repeats derived from prion, such as hexa- or octa-peptides) using a pH dependency mechanism - Google Patents
Method and use for the reversible aggregation and/or dissociation of polypeptides (comprising peptide repeats derived from prion, such as hexa- or octa-peptides) using a pH dependency mechanismInfo
- Publication number
- NZ543111A NZ543111A NZ543111A NZ54311104A NZ543111A NZ 543111 A NZ543111 A NZ 543111A NZ 543111 A NZ543111 A NZ 543111A NZ 54311104 A NZ54311104 A NZ 54311104A NZ 543111 A NZ543111 A NZ 543111A
- Authority
- NZ
- New Zealand
- Prior art keywords
- aggregation
- polypeptides
- polypeptide
- opr
- protein
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Neurology (AREA)
- Psychology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
An alternative method of reversible aggregation and/or dissociation of polypeptides is described. The proteins or polypeptides have an inherent aggregation capability, wherein the aggregation is an oligomerisation of the polypeptide that is based on the presence and the structure of peptide repeats localised in a flexibly disordered domain of this polypeptide. The flexibly disordered domain comprising the peptide repeats is located in close proximity with the N-terminus of the protein amino acid sequence. Preferably, each of the peptide repeats has a sequence that comprises one to four identical octapeptides with the amino acid sequence: PHGGGWGQ. Preferred proteins are selected from the group comprising cellular prion proteins (PrPc) and engineered polypeptides or fusion proteins with a respective inherent reversible aggregation and dissociation capability. Because of the mechanism of aggregation described, the oligomerisation reaction of the protein is reversible in a fluidic environment depending on the pH of this fluidic environment. Oligomerisation occurs at a pH of 6.2 to 7.8, and the dissociation into monomers is reported to be at a pH range of 4.5 to 5.5. Fig 1 shows the primary structure of the human prion protein
Description
■ 543111
PH-DEPENDENT POLYPEPTIDE AGGREGATION AND ITS USE
BACKGROUND OF THE INVENTION
The prion protein (PrP) was detected in attempts to identify the infective agent of transmissible spongiform encephalopathies (TSE), and consequently we know a lot about the pathological activity of the scrapie form, PrPsc, whereas the physiological function of the cellular form PrPc, remans an enigma (Prusiner, S.B. (1998) Prions. Proc Natl Acad Sci USA 95, 13363-13383). PrPc is a synaptic gly-
intellectual property office of n.z.
12 JAN 2007 RECEIVED
635361-1
coprotein with a heterogeneous distribution in healthy adult brain that is attached to the cell surface via a glycosyl phosphatidylinositol (GPI) anchor and partitions to membrane domains that have been termed lipid rafts. The localization of PrPc on the cell surface suggests that it may function in cell adhesion, ligand uptake or 5 transmembrane signaling.
Based on biochemical analyses of chicken PrPc, it was hypothesized that PrPc might be involved in regulating the expression of cholinergic receptors at synaptic endings. Indeed immunohistochemistry of PrPc-overexpressing transit) genie mice revealed a synaptic expression pattern with PrPc being predominantly located in the synaptic plasma membrane and, to a lesser extent, in synaptic vesicles. Electron microscopy showed that the protein is present both pre- and postsynaptically. PrPc has also been localized along elongating axons, and there is increasing evidence that PrPc may play a role in the growth of axons perhaps 15 as an adhesion protein.
The octapeptide repeat region, comprised of repeats of the sequence PHGGGWGQ, is among the most conserved segments of PrP in mammals (Schatzl, H.M., Da Costa, M., Taylor, L., Cohen, F.E. and Prusiner, S.B. (1995) 20 Prion protein gene variation among primates. J Mol Biol 245, 362-374; Wopfner, F., Weidenhofer, G., Schneider, R., von Brunn, A., Gilch, S., Schwarz, T.F., Werner, T. and Schatzl, H.M. (1999) Analysis of 27 mammalian and 9 avian PrPs reveals high conservation of flexible regions of the prion protein. J Mol Biol 289, 1163-1178). Residues 60 to 91 in human PrP consist of four His containing oc-25 tapeptide repeats (OPR), and residues 51 to 59 consist of the homologous sequence PQGGGGWGQ (Figure 1).
Figure 1 shows the primary structure of the human prion protein (hPrP). The mature human prion protein consists of residues 23 to 230. The detailed amino acid 30 sequence of the OPR region of residues 51 to 91 (gray boxes) is shown at the bottom, with residues unambiguously assigned in the nuclear magnetic reso
nance (NMR) spectra being underlined. For the segment 54-89 only a single set of resonance signals was detected for each repeated amino acid. Regular secondary structure elements are represented in black. The disulfide bond (S-S) between Cysl79 and Cys214 is drawn as a gray line. Arrows at the top indicate N-5 terminal truncations sites of the hPrP constructs used in this study.
The binding of copper to the OPR of mammalian and avian prion proteins was first demonstrated by Hornshaw and co-workers (Hornshaw, M.P., McDermott, J.R., Candy, J.M. and Lakey, J.H. (1995) Copper binding to the N-terminal tan-10 dem repeat region of mammalian and avian prion protein: structural studies using synthetic peptides. Biochem Biophys Res Commun 214, 993-999; Hornshaw, M.P., McDermott, J.R., Candy, J.M. and Lakey, J.H. (1995) Copper-Binding to the N-Terminal Tandem Repeat Region of Mammalian and Avian Prion Protein -Structural Studies Using Synthetic Peptides. Biochemical and Biophysical Re-15 search Communications 214, 993-999), and it has been suggested that copper-binding is involved in the physiological function of PrPc (Brown, D.R. et al. (1997) The cellular prion protein binds copper in vivo. Nature 390, 684-687). Recently, a heparin binding site has been identified within the OPR of PrPcf where binding is enhanced in the presence of Cu2+. The finding that the laminin receptor protein 20 acts as a receptor for PrPc in the presence of heparan sulfate suggests a complex interaction between prion protein, copper, heparin/heparan sulfate, and receptor proteins with implications for the cellular function of prion proteins. It has also been suggested that PrPc is released from synaptic vesicles to prevent unspecific copper binding of proteins in the synaptic cleft and that it supports the re-uptake 25 of copper into the presynapse through endocytosis.
PROBLEMS OBSERVED IN PRIOR ART
Transmissible spongiform encephalopathies (TSE) or prion diseases are fatal disorders of the central nervous system caused by unconventional infectious agents
(prions) that are composed of a prion protein (PrPSc) (Prusiner, S.B. (1998) Prions. Proc Natl Acad Sci USA 95, 13363-13383). The key event in TSE is the conformational change of a host protein, cellular prion protein (PrPc), encoded by the prion gene PRNP, into the neuropathological isoform PrPSc that aggregates 5 into amyloid fibrils and accumulates into neural and lymphoreticular cells (Doi, S., Ito, M., Shinagawa, M., Sato, G., Isomura, H. and Goto, H. (1988) Western blot detection of scrapie-associated fibril protein in tissues outside the central nervous system from preclinical scrapie-infected mice. J Gen Virol 69 (Pt 4), 955-960; Wadsworth, J.D.F., Joiner, S., Hill, A.F., Campbell, T.A., Desbruslais, M., Luthert, 10 P.J. and Collinge, J. (2001) Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive immunoblotting assay. Lancet 358, 171-180). Diagnostic strategies used for the detection of other infectious agents, such as PCR, are therefore useless. However, accurate diagnostic methods at early stages of clinical signs or during the pre-clinical phase of 15 the disease are needed as in vivo screening tests or the identification of infected individuals. These tests are not yet available, although enormous efforts have been made in the past years.
The formation of PrPSc occurs only in TSE and therefore is a specific marker for 20 these disorders. Despite the wide distribution of PrP50 and infectivity in the body of TSE-affected hosts, the histological and biochemical lesions are restricted only to the central nervous system (CNS), termed spongiform encephalopathy. In sporadic and genetic TSE, the tissue where PrPSc originates is unknown, but it is likely that PrPSc starts in the CNS, thus making the development of early diagnos-25 tic methods based upon the detection of PrPSc in easily accessible tissues or body fluids useless. During infection with prions PrP^ is readily detectable in lymphoreticular tissues (Doi, S. et al. (1988) Western blot detection of scrapie-associated fibril protein in tissues outside the central nervous system from preclinical scrapie-infected mice. J Gen Virol 69 ( Pt 4), 955-960) leading to the suggestion 30 of measuring PrPSc in tonsil tissue taken at biopsy for the diagnosis of scrapie in sheep and vCJD (Hill, A.F., Zeidler, M., Ironside, J. and Collinge, J. (1997) Diag
nosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy. Lancet 349, 99-100), a new variant of Creutzfeldt-Jakob disease that has been transmitted from BSE-infected cattle to human.
In recent years, great attention has been paid to the possible use of PrPSc detection in peripheral and accessible tissues (such as tonsil) or body fluids (such as the cerebrospinal fluid (CSF) or blood) for preclinical in vivo diagnostic of TSE. Experimental data failed to detect infectivity in blood of patients affected with any form of human TSE, but an exception could be vCJD patients where concern 10 about the infectivity in blood has been raised, mostly because of the high level of PrPSc and infectivity in the lymphoreticular tissues.
From the perspective of pre-clinical diagnosis, the sensitivity of diagnostic methods and the procedures to concentrate PrPSc become crucial because the amount 15 of PrPSc outside the CNS might be extremely small. The detection limit of currently available PrPSc detection methods, such as ELISA , is about 2 pM (Ingros-so, L., Vetrugno, V., Cardone, F. and Pocchiari, M. (2002) Molecular diagnostics of transmissible spongiform encephalopathies. Trends in Molecular Medicine 8, 273-280). An improved extractions method for PrP^ with sodium phosphotung-20 state (Wadsworth, J.D.F. et al. (2001) Tissue distribution of protease resistant prion protein in variant Creutzfeldt-Jakob disease using a highly sensitive im-munoblotting assay. Lancet 358, 171-180) and newly discovered molecules, such as plasminogen (Fischer, M.B., Roeckl, C., Parizek, P., Schwarz, H.P. and Aguzzi, A. (2000) Binding of disease-associated prion protein to plasminogen. Nature 25 408, 479-483) and protocadherin-2 (Brown, P., Cervenakova, L. and Diringer, H. (2001) Blood infectivity and the prospects for a diagnostic screening test in Creutzfeldt-Jakob disease. J Lab Clin Med 137, 5-13) binding with high affinity to PrPSc, might boost new hopes for preclinical diagnostics of TSE. An original approach to increase the minimum detectable level of PrP50 comes from Saborio and 30 co-worker (Saborio, G.P., Permanne, B. and Soto, C. (2001) Sensitive detection of pathological prion protein by cyclic amplification of protein misfolding. Nature
411, 810-813), who developed an efficient protocol for the 10-100-fold amplification of PrPsc.
OBJECTS AND SUMMARY OF THE INVENTION
It is therefore an object of the invention to provide an alternative possibility to reversibly aggregate/dissociate polypeptides. It is also an object of the invention to provide ligands that selectively bind to the three-dimensional structure of such polypeptide aggregates. It is a further object of the present invention to provide sensors, 10 which detect binding of ligands to the three-dimensional structures of such polypeptide aggregates. The invention aims to achieve at least one of the stated objects.
In a first embodiment of the invention there is provided a method for the reversible aggregation and/or dissociation of polypeptides, comprising the step of oligomerising a polypeptide at a pH of 6.2 to 7.8 and/or dissociating a polypeptide 15 aggregate at a pH of 4.5 to 5.5 in a fluid environment, wherein the polypeptide is characterized in that
(i) the polypeptide comprises one or more peptide repeat structures derived from prion proteins;
(ii) and that the protein oligomerizes in fluid at pH of 6.2 to 7.8 and 20 dissociates into monomers at a pH of 4.5 to 5.5.
In a second embodiment of the invention there is provided use of a method according to the first embodiment for detecting human or animal prion proteins.
In a third embodiment of the invention there is provided use of a method according to the first embodiment for affinity purification and/or enrichment of said 25 polypeptides.
In a fourth embodiment of the invention there is provided use of a method according to the first embodiment for chemical and/or physical sensor technology.
Structural studies of mammalian prion protein at pH values between 4.5 and 5.5 established that the N-terminal 100-residue domain is flexibly disordered, i.e., has random 30 coil information. This invention describes that at pH values between 6.5 and 7.8, i.e., the pH at the cell membrane, the octapeptide repeats in recombinant human prion protein hPrP (23-230) encompassing the highly conserved sequence PHGGGWGQ are structured. The nuclear magnetic resonance (NMR) solution structure of the OPR at pH 6.2 reveals a new structural motif that causes a reversible pH-dependent PrP
635361-1
intellectual property office of n.z.
12 JAN 2007
n f~ r* i i # r- r-%
6a oligomerization into macromolecular aggregates. Comparison with the crystal structure of HGGGW-Cu2+ indicates that the binding of copper ions induces a conformational transition that presumably modulates PrP aggregation. These results suggest a functional role of the cellular prion protein in homophilic cell adhesion with the synaptic cleft.
intellectual property office of n.z.
12 JAN 2007 RECEIVED
Bioreceptors can provide the basis for specific and sensitive biosensors (Schultz, JS. (1987) Sensitivity and dynamics of bioreceptor-based biosensors. Ann. N Y Acad. Sci. 506, 406-414). There are many sources of bioreceptors in nature for biochemicals of interest in biotechnology and biomedicine. These bioreceptors 5 (antibodies, enzymes, membrane proteins, binding proteins) can be modified and produced in large quantities using modern biotechnological techniques (Rigler, P., Ulrich, W.P., Hoffmann, P., Mayer, M. and Vogel, H. (2003) Reversible immobilization of peptides: surface modification and in situ detection by attenuated total reflection FTIR spectroscopy. Chemphyschem. 4, 268-275). The characteristics of 10 the biosensor can also be fine-tuned by modifying the structure of the analog-analyte, which will also provide several orders of magnitude of range sensitivity with a given bioreceptor. The ultimate sensitivity of the biosensor may be limited by the dissociation kinetics of the reaction between analyte and bioreceptor because there is a trade-off between sensitivity and sensor response rate to 15 changes in analyte concentration.
Advantages of the present invention comprise:
• Polypeptides or proteins with inherent aggregation capability can be oligo-merized by the presence and the structure of peptide repeats localized in a domain of this polypeptide which is flexibly disordered dependent of the pH.
• The peptide repeats required for reversible polypeptide aggregation/dissoci-25 ation may be - alone or together with a flexibly disordered protein domain -
part of the native amino acid sequence or may be introduced by posttransla-tional modification of a polypeptide or protein.
o Oligomerization only is dependent on the pH of the fluidic environment of the 30 polypeptides or proteins.
BRIEF DESCRIPTION OF THE FIGURES
The following figures are intended to document prior art as well as the invention. Preferred embodiments of the method in accordance with the invention will also be explained by means of the figures, without this being intended to limit the scope of the invention.
Fig. 1. Primary structure of the human prion protein;
Fig. 2. Apparent molecular weight of hPrP polypeptides;
Fig. 3. pD dependence of hPrP *H NMR spectrum:
Fig. 3A hPrP(23-230);
Fig. 3B hPrP(81-230);
Fig. 3C hPrP(90-230);
Fig. 4. Stereo views of octapeptide repeat structures:
Fig. 4A 20 energy-refined DYANA conformers of HGGGWGQP; Fig. 4B Space-filling model of (HGGGWGQP)3?
Fig. 4C Comparison of HGGGWGQ and the X-ray structure of HGGGW-Cuz+;
Fig. 5.
Backbone mobility of hPrP(23-230).
DETAILED DESCRIPTION OF THE INVENTION
NMR solution structures have been described for recombinant forms of intact 5 human (Zahn, R. et al. (2000) NMR solution structure of the human prion protein. Proc Natl Acad Sci USA 97, 145-150), bovine, and murine PrP at pH 4.5, and of the Syrian hamster PrP at pH 5.5. Under acidic conditions, all prion proteins contain a C-terminal globular domain that extends approximately from residues 121-230 containing a two-stranded anti-parallel p-sheet and three a-heli-10 ces, and an N-terminal domain encompassing residues 23-120 that is flexibly disordered (Figure 1). At pH 7.3, the average interstitial milieu of the brain, there is no detailed structural information available, except for the NMR structure of a C-terminal fragment corresponding to the globular domain of human prion protein, hPrP(121-230), determined at pH 7 (Luigi Calzolai and R.Z., unpublished 15 results) that is largely similar to the structure at acidic conditions (Zahn et al., 2000). In the crystal structure of dimeric hPrP(90-231) that has been recently determined from crystals grown in pH 8 solution, the two globular domains are linked through interchain disulfide bonds.
In an attempt to investigate possible effects of pH on the structure of PrPc we have studied the recombinant human prion protein (hPrP) in solution using NMR spectroscopy and dynamic light scattering. For these studies we have produced recombinant hPrP(23-230) corresponding to mature PrPc as well as two N-termi-nally truncated PrP constructs (Figure 1). We find that protonation of the four 25 OPR-histidines results in PrP aggregation. From distance constraint calculations of 1SN-Iabelled hPrP(23-230) we have calculated the NMR structure of the OPR in pH 6.2 solution. This structure is compared with the recently determined crystal structure of the copper binding octapeptide repeat segment HGGGW-Cu2+
(Burns, C.S. et al. (2002) Molecular features of the copper binding sites in the 30 octarepeat domain of the prion protein. Biochemistry 41, 3991-4001). The re-
suits are evaluated with regard to possible functional roles of the OPR in PrPc in the presence and absence of copper.
Furthermore, this invention includes the following applications:
o The provision and application of a new kind of screening test as well as accurate diagnostic methods at early stages of clinical signs or during the preclinical phase of TSE (Transmissible Spongiform Encephalopathies), in particular vCJD (new variant of Creutzfeldt-Jakob disease).
• The immobilization of OPR-tagged fusion proteins or polypeptides to a solid phase, such as resins, glass beads etc., allows a new kind of affinity purification, enrichment or detection of OPR-tagged fusion proteins or polypeptides to be provided and/or applied.
• The provision of OPR-tagged fusion proteins or polypeptides and their application for a new kind of pH dependent molecular switches for IT technologies, or for molecular sensors or machines working on a molecular level.
• The provision of OPR-tagged fusion proteins or polypeptides that specifically recognize prion proteins as a therapeutic agent against TSE as well as the provision of gene therapy vectors for the therapy of vCJD.
• The provision of OPR-tagged fusion proteins or polypeptides for the production of polyclonal, monoclonal, and/or engineered antibodies.
• The provision of ligands that selectively bind to the three-dimensional structure of such polypeptide aggregates. Such ligands comprise prion proteins (PrPc and PrPSc), antibodies, chemical molecules, and octapeptide-containing fusion proteins.
• The provision of OPR-tagged fusion proteins or polypeptides for sensor technology, including chemical (e.g., biochemical) and/or physical (e.g., optical) sensor chips.
EXPERIMENTAL RESULTS
1. Production and Spectroscopic Characterization of Human Prion Proteins: The following polypeptides were prepared for the present study (Figure 1): the
mature form of the human prion protein, hPrP(23-230); hPrP(81-230), containing a single octapeptide; hPrP(90-230), completely lacking the OPR and corresponding approximately to the minimal sequence required for prion propagation; and hPrP(121-230), corresponding to the well-structured globular PrP domain (Zahn et al., 2002). This array of constructs enabled investigations of possible in-15 fluences of the overall chain length on the solution characteristics of human prion proteins.
2. Influence of pH on Hydrodynamic Radius of Human Prion Proteins:
The hydrodynamic radius (Rh) of hPrP polypeptides was determined from dynamic light scattering measurements as summarized in Figure 2.
Figure 2 shows the apparent molecular weight of hPrP polypeptides. Dynamic light scattering measurements were carried out at 20 °C with 4 mg/ml protein 25 solutions buffered with 10 mM sodium acetate at pH 4.5 (light gray bars), 10 mM sodium phosphate at pH 7.0 (dark gray bars), or 10 mM sodium acetate at pH 4.5 and containing 100 mM sodium chloride (black bars). Standard errors are given for 4 independent measurements with 30 data points each. The arrow indicates that the apparent molecular weight of hPrP(23-230) at pH 7.0 is larger 30 than 4 MDa.
WO 2004/085464 PCT/EP2004/003060
At pH 4.5, Rh of hPrP(121-230) is in good agreement with the molecular size of the monomeric protein. When assuming a spherical globular shape for the C-terminal domain, the estimated apparent molecular weight of hPrP(121-230) is 15.1 kDa compared to 13.1 kDa as calculated from the amino acid sequence. The 5 N-terminal domain of residues 23-120 only slightly reduced the diffusion rate of hPrP molecules in pH 4.5 solution, but, in the presence of 100 mM sodium chloride there was an increase in RH with increasing length of the l\l-terminus. The effect of salt on apparent molecular weight is rather unspecific as it does not depend on a specific sequence motif.
At pH 7.0, however, immediate precipitation of hPrP(23-230) upon adjusting the protein solution from pH 4.5 to pH 7 precluded an estimation of Rh using dynamic light scattering (Figure 2), indicating that the particle size of hPrP aggregates was > 4 MDa. Size exclusion chromatography experiments failed to identify the mo-15 lecular size of PrP aggregates more exactly because the protein interacted with the agarose-dextran gel, presumably owing to an affinity of the OPR for the polysaccharide (Hundt, C. et al. (2001) Identification of interaction domains of the prion protein with its 37-kDa/67-kDa laminin receptor. Embo Journal 20, 5876-.5886). In contrast, the C-terminal fragments hPrP(81-230), hPrP(90-230) and 20 hPrP(121-230) only showed a slight increase in Rh when compared to the measurements in pH 4.5 solution at low ionic strength, indicating that the highly specific aggregation of hPrP(23-230) into macromolecular protein particles can be attributed to the N-terminal segment of residues 23 to 89 encompassing the OPR (Figure 1).
3. Influence of pD on *H NMR Linewidth of Human Prion Proteins:
To further characterize the pH-dependent aggregation of hPrP(23-230) we performed *H NMR experiments at various solution conditions. *H linewidths in NMR 30 experiments are approximately proportional to the overall rotational correlation time (tc) and thus depends on the molecular mass and shape of the molecule.
Linewidths significantly larger than expected based on the molecular mass of a protein imply either an increase in %c due to aggregation or that chemical exchange or conformational exchange effects contribute significantly to the linewidth.
Figure 3 shows the pD dependence of hPrP XH NMR spectrum. Shown is the spectral region from 6 to 9 ppm in the 750 MHz *H NMR spectrum of a 0.6 mM solution of hPrP in D20 at 20 °C. (A) hPrP(23-230). (B) hPrP(81-230). (C) hPrP(90-230). Prior to these experiments, the labile protons were exchanged with deuter-10 ons by dissolving samples in D20. Subsequently, the pD of the sample was increased in a stepwise fashion (see arrow bottom to top) by adding small amount of NaOD, before decreasing it again to pD 4.5 by small additions of DCI. Resonance assignments for selected aromatic resonance signals are indicated at the top of each spectrum.
Figure 3A shows the spectral region from 6 to 9 ppm in the *H NMR spectrum of hPrP(23-230) recorded in D20. At pD 4.5, the aromatic ring protons of His, Phe and Tyr residues located within the folded C-terminal domain show linewidths typical for a globular protein of about 23 kDa. The less dispersed resonance lines 20 of the flexibly disordered tail such as the overlapping resonances of HEl of histidi-nes 61, 69, 77 and 85 are significantly narrower because their effective tc is smaller due to the increased mobility in the tail. As the pD was increased stepwise from 4.5 to 8, the HEl resonances of His shifted up-field and the *H linewidths generally increases, as shown for the aromatic ring protons in Figure 25 3A. The changes were reversible as indicated by the top spectrum. Repeating the same experiment with hPrP(81-230) resulted in a slight line broadening of resonance signals (Figure 3B), whereas for hPrP(90-230) the linewidth was independent on pD (Figure 3C).
As these measurements were performed in D20 where only non-exchangeable protons are detected, we can rule out chemical exchange as a possible source for
the observed uniform line broadening in the NMR spectra. Furthermore, an exclusive effect of conformational exchange on linewidth would be considerably smaller than is observed in Figure 3A, and the recorded NMR spectra do not resemble that of a molten globule protein with poorly dispersed resonances 5 (Dyson, H.J. and Wright, P.E. (2001) Nuclear magnetic resonance methods for elucidation of structure and dynamics in disordered states. Nuclear Magnetic Resonance of Biological Macromolecules, PtB 339, 258-270). More likely, and in accordance with the dynamic light scattering experiments (Figure 2), the progressive broadening of NMR peaks at pD values between 6.0 and 8.0 is caused 10 by protein aggregation owing to the deprotonation of His side chains within the peptide segment 23-89, i.e. the four OPR-histidines (Figure 1), resulting in the observed up-field shift of HEl resonances (Figure 3A). There was no line broadening in [15N,1H]-correlation spectroscopy (COSY) spectra recorded with equimolar mixtures of unlabelled hPrP(23-230) and 15N-labelled hPrP(121-230) in H20 solu-15 tion at pH 7.0 (data not shown), indicating that the binding epitope of the OPR is located within the N-terminal segment 23-120.
4. Resonance Assignment of the N-terminal Domain at pH 6.2:
Sequence specific assignments of backbone amide protons and nitrogens of the
N-terminal segment 23-120 at pH 6.2 was obtained from [15N,1H]-COSY pH-
titration experiments with 1SN-Iabeled hPrP(23-230) based on chemical shift comparison with spectra recorded at pH 4.5 (Liu, A.Z., Riek, R., Wider, G., von
Schroetter, C., Zahn, R. and Wuthrich, K. (2000) NMR experiments for resonance
assignments of C-13, N-15 doubly-labeled flexible polypeptides: Application to the human prion protein hPrP(23-230). Journal of Biomolecular Nmr 16,127-
138). At pH 6.2, where about 40% of the unperturbed histidlnes are deproto-
nated, the resonance lines in the ["N/HJ-COSY spectrum are only slightly broadened, indicating that a large fraction of PrP molecules is monomeric under 30 these conditions. The backbone assignments were confirmed using a three-
dimensional lsN-resolved j^H/HJ-nuclear Overhauser enhancement spectroscopy
(NOESY) spectrum, which was subsequently used for assignment of side chain protons. All polypeptide backbone resonances were assigned, excluding the amide nitrogens and amide protons of G!y35, Gly93 and Gly94, which are overlapped with those of Gly residues in the OPR region (Liu et al., 2000). Corre-5 sponding resonance lines of the individual OPR segments overlap completely, except for the two flanking dipeptides Gln52-Gly53 and Gly90-Gln91 (Figure 1), i.e. the resonance of a given atom from a given residue in the octapeptide occur at the same frequency for all five repeats. Among the labile side chain protons, the amide groups of all 4 Asn and 8 Gin residues could be assigned using intrare-10 sidual NOEs, with the sole exception of Gln59. The e-proton resonances of the 3 Arg residues could not be detected at pH 6.2 due to fast exchange with the solvent.
5. Collection of Conformational Constraints and Structure Calculations of the N-terminal Domain at pH 6.2:
For assignment of NOESY cross peaks we used the automatic NOE assignment software CANDID in combination with the structure calculation program DYANA. At the outset of the structure calculation of the peptide segment 23-120 In 20 hPrP(23-230), a total of 689 NOESY cross peaks were assigned and integrated in the ISN-resolved ^H/HJ-NOESY spectrum recorded at pH 6.2, which yielded 322 NOE upper limit distance constrains. Strikingly, a total of 219 NOESY cross peaks could be identified as originating from amide nitrogens and protons of the OPR region at pH 6.2, whereas only 98 such peaks are observed at pH 4.5 (Liu et al., 25 2002). This indicated the presence of additional structured regions in the OPR at pH 6.2, which are not stable at pH 4.5. In contrast, no additional NOESY cross peaks could be identified for residues outside the OPR, indicating that the pH-dependent structure formation is limited to this region.
Every cross peak within the lsN-resolved [lH,1H]-NOESY could be the result of an interaction of an amide proton with a second proton of the same octapeptide or
with one of the other octapeptides. To investigate the compatibility of the NOESY cross peaks with intra- and inter-octapeptide assignments, we performed a structure calculation of a 16-residue peptide (PHGGGWGQ)2 corresponding to two OPR using the programs CANDID and DYANA, where the same chemical shifts were 5 attributed to corresponding atoms of a given residue within the two OPR. Out of the resulting 80 NOE upper distance constraints 11 constraints were assigned as inter-octapeptide involving the C-terminal Gin of the first octapeptide: 7 sequential (i,i+l) NOEs with Pro, 2 medium-range (i,i+2) NOEs with His, and 2 long-range (i,i+5) NOEs with Trp.
To further improve the structure calculation of OPR we investigated the compatibility of the NOESY cross peaks with various possible assignments within a single octapepide. We performed a series of CANDID / DYANA structure calculations using the same peak list as an input, except that the amino acid sequence within 15 the chemical shift list was varied with respect to the standard OPR sequence
PHGGGWGQ (Figure 1). The results in Table 1 show that all eight structure calculations converged with a residual DYANA target function value close to 1.
Table 1: Characterization of OPR Calculated after NOE Assignment with CANDID 20 and DYANA3
Target Functionc
Sequence
NOEs"
1 OPR
2 OPR
3 OPR
4 OPR
PHGGGWGQ
110
0.42 ± 0.05
2.09 ±0.85
.14 ±1.32
.16 ± 1.68
HGGGWGQP
98
0.28 ± 0.02
0.62 ±0.07
1.12 ±0.19
1.18 ±0.17
GGGWGQPH
93
0.55 + 0.03
1.11 ±0.04
2.40 ± 0.91
4.64 ± 1.66
GGWGQPHG
96
0.66 ± 0.58
3.66 ±1.93
6.39 ± 2.59
11.1 ±3.58
GWGQPHGG
96
0.05 ±0.01
4.65 ± 1.36
.72 ± 3.90
9.78 ± 6.03
WGQPHGGG
98
0.97 ±0.12
2.75 ± 0.65
.67 ±1.22
9.91 ± 1.89
GQPHGGGW
102
1.11 ±0.29
2.90 ± 0.84
7.15 ±1.96
11.4 ±3.03
QPHGGGWG
102
1.13 ±0.12
2.63 ± 0.24
.58 + 1.06
9.51 ± 2.35
Captions to Table 1:
a Eight different variant octapeptide sequences were generated by starting at different sequence positions within the OPR region of residues 60-91 (Figure 1). The input for the DYANA calculations with segments of two, three and four 5 OPR was adapted from the seventh cycle of the CANDID / DYANA output of a single OPR the sequence of which is listed in the first column. Each calculation was started with 100 randomized structures.
b Number of NOE upper distance constraints in the input of each OPR.
c Residual DYANA target function value (A2). The average ± standard deviation is 10 given for a bundle of 20 conformers used to represent the structure.
However, when the DYANA calculations were repeated using the same distance constraints but for peptides containing two, three or four consecutive OPR, the resulting structures converged with different target function values. Constantly 15 small residual constraint violations were only obtained for those peptides with the repetitive sequence element HGGGWGQP (Table 1), indicating that these structures are mostly consistent with the experimental constraints and are thus steri-cally more favorable than the structures of the other seven octapeptide sequences.
The 20 best DYANA conformers used to represent the NMR structure of the 8-residue peptide HGGGWGQP and the 24-residue peptide (HGGGWGQP)3/ corresponding to residues 61 to 84 of hPrP(23-230) (Figure 1), were further energy-refined with the program OPALp. Table 2 gives a survey of the results of the 25 structure calculation.
Table 2: Characterization of the 20 Energy-refined DYANA Conformers Representing the NMR Structures of HGGGWGQP and (HGGGWGQP)3
Quantity
Value1
HGGGWGQP
(HGGGWGQP)3
Residual DYANA target function value (A2)2
0.28 + 0.02
1.12 ±0.19
Residual NOE distance constraint violations
Number > 0.1 A
1±1
2 ± 2
Maximum (A)
0.10 + 0.01
0.11 ±0.00
AMBER energy (kcal/mol)
Total
-6819 + 341
-6850 ± 200
van der Waals
+•13 + 18
-7 ±22
Electrostatic
-8569 ± 324
-8589 ± 204
RMSD from ideal g eometry
Bond lengths (A)
0.0078 ±0.0001
0.0079 ± 0.0001
Bond angles (degrees)
1.88 ± 0.03
1.91 ±0.03
RMSD, N, C°, C' (A)3
0.26 ± 0.05
3.19 ±0.80
RMSD, all heavy atoms (A)3
0.62 ± 0.09
3.52 ±0.88
Captions to Table 2:
1 Average values ± standard deviations for the 20 energy-minimized conformers with the lowest DYANA target function values are given. The input consisted of 98 and 294 NOE upper distance constraints for HGGGWGQP and (HGGGWGQP)3, respectively.
2 Before energy minimization.
? RMSD values relative to the mean coordinates.
Table 2 shows that the global RMSD values among the bundle of 20 conformers of HGGGWGQP are representative of a high-quality structure determination (Figure 4A), whereas the NMR structure of (HGGGWGQP)3 is less precisely defined 15 because of the missing assignments of long-range NOEs connecting the OPR.
Figure 4 shows stereo views of octapeptide repeat structures. (A) All-heavy-atom representation of the 20 energy-refined DYANA conformers superimposed for best fit of the N, C° and C' atoms of HGGGWGQP. The backbone is gray and the
side chains are shown in different colors: Trp (yellow), His (cyan), Gin (pink) and Pro (orange). (B) Space-filling model of (HGGGWGQP)3. The numbering corresponds to residues 61 to 84 in the human prion protein sequence (Figure 1). The same color code as in (A) was used. (C) Comparison of the NMR structure of 5 HGGGWGQP and the X-ray structure of HGGGW-Cu2+ (Burns et al., 2002). The relative orientation of the two molecules resulted from a superposition for best fit of the backbone heavy atoms of the pentapeptide segment HGGGW (RMSD 1.3 A). The backbone and side chain heavy atoms of the NMR structure are in green. In the X-ray structure the oxygen, nitrogen, carbon and hydrogen atoms are dis-10 played in red, blue, gray and white, respectively. Hydrogen bonds between the pentapeptide and ordered water molecules are indicated as white dashed lines. The position of the copper ion is indicated by a sphere in cyan (for illustrative purposes, the copper radius is not scaled to reflect the true atomic radius). The red and blue lines indicate the copper coordination sites between copper and the 15 peptide oxygen and nitrogen atoms, respectively.
6. NMR Structure of Octapeptide Repeats (HGGGWGQP) and (HGGGWGQP)3: The NMR structure of HGGGWGQP has the same global fold as the corresponding 20 OPR in (HGGGWGQP)3/ with an RMSD value of 0.32 A between the backbone heavy atoms In the mean structures of HGGGWGQP and the N-terminal octapeptide of (HGGGWGQP)3 corresponding to residues 61-68 of hPrP(23-230). The segments HGGGW and GWGQ adopt a loop conformation and a 3-turn structure, respectively, where the 0-turn is corroborated by a continuous pattern of dm and 25 d0N NOE connectivities, and a c/aN(i,i+2) NOE connectivity between Trp and Gin. In (HGGGWGQP)3 the octapeptides are arranged to form a triangular globular domain (Figure 4B). This molecular architecture is stabilized by a repetitive set of hydrogen bonds: each of the three OPR contains three intra-octapeptide hydrogen bonds His(/) HN-0* Gln(/+6), Gly(/+2) H^N*2 His(/) and Trp(/+3) HE-0' 30 Gly(/). The contacts between the three OPR are stabilized by two hydrogen bonds of the type Gly(/+2) HN-0' Pro(/'). The peptide bonds of Gln(/")-Pro(/'+I) are in
WO 2004/085464 PCT/EP2004/003060
trans conformation. All side chain atoms are largely solvent exposed including the hydrophobic side chains of Trp (Figure 4B). From the three-dimensional structure of the OPR it thus appears likely that the symmetric distribution of solvent exposed hydrophobic residues is of importance for PrP aggregation.
7. Backbone Dynamics of hPrP(23-230) at pH 6.2:
The formation of tertiary structure interactions at pH 6.2 within the OPR correlates with intramolecular rate processes that may be detected by measurement 10 of heteronuclear 15N<1H>-NOEs. In previous studies in pH 4.5 solution (Zahn et al., 2002) the N-terminal domain comprising residues 23-120 of hPrP(23-230) showed exclusively negative NOEs, contrasting with the C-terminal domain which displayed values typical for a globular structured domain. Thus, the effective rotational correlation times, tc, could be estimated to be at least several nanosec-15 onds for the backbone lsN-1H moieties of the C-terminal domain, whereas the 1SN-1H moieties in the N-terminal domain must have xc < 1 ns as would be expected for a flexible random coil-like polypeptide chain. In contrast, at pH 6.2 some of the 15N-1H moieties of the N-terminal domain, including the OPR and several residues flanking the OPR (Figure 5), show positive 15N{1H>-NOEs of 20 about 0.2 indicating that this polypeptide region is folded into a globular structure with a certain degree of mobility, presumably because it is in equilibrium with more unfolded conformations.
Figure 5 shows the backbone mobility of hPrP(23-230). Steady-state 1SN{1H>-25 NOEs of amide groups were measured in a 0.5 mM solution of hPrP(23-230) in 90% H2O/10% D20 at pH 6.2 and 20 °C. In the box from positions 51 to 91 the circles indicate that patterns are identical for all five repeats due to the degenerate chemical shifts (see text). The arrow indicates that the 15N{1H>-NOEs are lower than -1 for Lys23 and Lys24. Some of the lsN{1H>-NOEs could not be 30 quantified because of spectral overlap.
In addition to the backbone amide groups the Trp indole 15Ne—1H moieties of the OPR were characterized by NOE values close to zero, implying that the side chains may be involved in transient tertiary structure interactions, in agreement with the results from the structure calculations. Although the aggregation of 5 hPrP(23-230) at pH values higher than 6.2 precluded a detailed NMR characterization under these conditions, it appears likely that the globular structure of OPR is further stabilized at pH 7 because of the increased degree of deprotonation of the histidines.
DISCUSSION OF THE RESULTS
1. Octapeptide Repeat Structure Represents a New Structural Motif: The program DALI (Holm, L. and Sander, C. (1993) Protein-Structure Compari-15 son by Alignment of Distance Matrices. Journal of Molecular Biology 233, 123-138) revealed no significant similarity between the structures of HGGGWGQP and (HGGGWGQP)3 described here with any of the previous deposits in the Protein Data Bank, indicating that the OPR structure represents a new structural motive. The results of our structure calculations deviate from previous structural studies 20 on synthetic OPR peptides. From circular dichroisrh experiments at pH 7.4 it was suggested that the OPR adopt an extended conformation with properties similar to a poly-L-proline type II helix (Smith, C.J., Drake, A.F., Banfield, B.A., Bloomberg, G.B., Palmer, M.S., Clarke, A.R. and Collinge, J. (1997) Conformational properties of the prion octa-repeat and hydrophobic sequences. Febs Letters 25 405, 378-384), whereas a recent NMR study carried out between pH 6.2 and 6.6 suggests that the segments HGGGW and GWGQ adopt a loop conformation and a (3-turn, respectively (Yoshida, H., Matsushima, N., Kumaki, Y., Nakata, M. and Hikichi, K. (2000) NMR studies of model peptides of PHGGGWGQ repeats within the N-terminus of prion proteins: A loop conformation with histidine and trypto-30 phan in close proximity. Journal of Biochemistry 128, 271-281). Although we also observe a turn-like conformation for segment GWGQ (Figure 4A), the loop
conformation in our structure is different because a close proximity of the imidazole side chain of His to the aromatic ring of Trp is not supported from our structure calculation. Because NMR data on cyclized OPR encompassing one or two oc-tapeptides also do not suggest a close proximity of His and Trp side chains (Yo-5 shida et al., 2000) this interaction might only transiently be formed.
Variants of mammal octapeptides comprise sequences, such as PHGGSWGQ (mouse) and PHGGGWSQ (rat) or pseudooctapeptides, e.g. deriving from these octapeptides, with more or less than eight amino acids, such as PHGGGGWSQ 10 (various species) or PHGGGSNWGQ (marsupial). Non-mammal hexapeptides comprise sequences, such as PHNPGY (chicken) or PHNPSY, PHNPGY (turtle) or pseudohexapeptides, e.g. deriving from these hexapeptides, with more or less than six amino acids. The sequences discussed here are to be understood as examples that do not limit the gist of this invention.
2. Possible Role of Copper in Modulation of pH-dependent PrP Aggregation: Unexpectedly, the HGGGW loop in the NMR structure of HGGGWGQP has a similar backbone fold as the corresponding resides in the crystal structure of the cop-20 per binding octapeptide repeat segment HGGGW-Cu2+ recently determined from crystals grown at pH 7.4 (Burns, C.S. et al. (2002) Molecular features of the copper binding sites in the octarepeat domain of the prion protein. Biochemistry 41, 3991-4001). In the structure of HGGGW-Cuz+ (Figure 4C), Cu2+ is pentacoordi-nated with equatorial ligation from the 51-nitrogen of the His imidazole and the 25 amide nitrogens from the next two Gly residues of which the second Gly also contributes its amide carbonyl oxygen. With the exception of the His backbone nitrogen and C°, all atoms from the His through the nitrogen of the third Gly lie approximately in the equatorial plane and the copper is just above this plane, consistent with a pentacoordinate complex. The Trp indole also participates 30 through a hydrogen bond to the axially coordinated water molecule, whereas glutamine is the only side chain possessing a functional group that does not par-
ticipitate in copper binding. From their data Burns and co-workers suggested a model where exposed glutamine side chains within two "metal sandwich" octapeptide repeats of membrane bound PrP may serve as an interaction site for intermolecular recognition between PrP molecules, and thus stimulating copper 5 induced endocytosis (Pauly, P.C. and Harris, D.A. (1998) Copper stimulates en-docytosis of the prion protein. J Biol Chem 273, 33107-33110) or facilitating the formation of PrPSc.
Although the NMR structure of the copper-free HGGGW-loop has a similar back-10 bone conformation to the corresponding residues in HGGGW-Cu2+, with an RMSD value of 1.3 A between the backbone heavy atoms of the two pentapeptides (Figure 4C), there are obvious conformational differences for the aromatic side chains involved in cooper coordination in the HGGGW-Cu2+ structure. In the copper-free HGGGW the His imidazole shifts below and tilts towards the equatorial 15 plane of the copper pentacoordinate complex in the HGGGW-Cu2+ structure, resulting in an increase of the distance between the 51-nitrogen of His and the Cu2+ binding site from 1.9 A to 3.5 A. Furthermore, the Trp indole in HGGGW is flipped by about 180° around a virtual axis parallel to one passing through the coordinating nitrogen and Cu2+, thus precluding the formation of a hydrogen 20 bond between eNH of Trp and the oxygen atom of the axial water molecule observed in the HGGGW-Cu2+ structure.
From the combination of the structural and biochemical data reported here and in previous publications (Aronoff-Spencer, E. et al. (2000) Identification of the Cu2+ 25 binding sites in the N-terminal domain of the prion protein by EPR and CD spectroscopy. Biochemistry 39, 13760-13771; Viles, J.H., Cohen, F.E., Prusiner, S.B., Goodin, D.B., Wright, P.E. and Dyson, HJ. (1999) Copper binding to the prion protein: structural implications of four identical cooperative binding sites. Proc Natl Acad Sci USA 96, 2042-2047) the conformation of the HGGGW-loop within 30 the OPR appears to depend on both pH and copper binding:
PrP <:
£ PrP + Cu2+
-Cu2+
A
(1)
pfl 5 pH 7
pH 5 pH 7
(PrP)agg
According to scheme (1), at pH values between 4.7 and 5.8, i.e. the pH of en-10 dosome-like compartments, the OPR-histidines are largely protonated: consequently, the OPR are flexibly disordered and bind copper only with low affinity and cooperativity. At pH values between 6.5 and 7.8, i.e. the pH at the cell membrane, the OPR-histidines are predominantly deprotonated, thus stabilizing the HGGGW-loop conformation which promotes aggregation, and if present, Cu2+ 15 is incorporated into the copper binding sites. The coordination of copper by
HGGGW results in a slight but significant conformational change that presumably leads to a structural change in PrP aggregates. The function of copper could thus be that of a modulator of pH-dependent PrP aggregation, although it remains to be shown if the binding of Cu2+ is compatible with a reverse aggregation of the 20 OPR into dimeric or oligomeric protein aggregates.
It was not known in the prior art that PrPc forms large protein aggregates. In addition, the finding that aggregation of PrPc is dependent on the pH of the fluidic environment is new. Moreover, it was not known that the OPR are responsible for 25 the pH dependent aggregation of PrP° and that a conformational change is involved in the pH dependence of the aggregation of this OPR. Present database are void of 3D structures similar to that reported in Fig. 4. The oligomerization reaction depends on the pH of the fluidic environment and oligomerization occurs also in absence of monovalent or divalent cations, such as Hg2+, Ni2+, Sn2+ or 30 Cu2+ ions.
3. Implications of pH-dependent Aggregation on PrPc Physiological Function: Assuming that natural PrPc behaves similarly in vivo as compared to the recombinant hPrP, its aggregation state may also largely depend on the environmental pH. The His containing OPR could therefore act as a pH-dependent aggregation 5 site that concentrates a large number of PrPc molecules within the lipid rafts of the presynaptic membrane surface. A lipid raft of 44 nm diameter, would provide enough surface for about 80 PrPc molecules with a diameter of 5 nm. Thus, the physiological role of copper could be to modulate the number of PrPc molecules within the lipid rafts, thereby stimulating PrPc endocytosis into presynaptic vesi-10 cles, where the prion proteins would dissociate into monomers because of the locally acidic pH. This model would be in line with a proposal of Burns and coworkers (Burns et al., 2002), except that copper acts as a modulator rather than an inducer of PrPc aggregation.
Alternatively, the OPR in mammalian PrPc may serve as an intercellular contact site for cell-cell adhesion between neuronal axons and dendrites. A potential involvement of PrPc in cell adhesion has recently been demonstrated by Lehmann and colleagues (Mange, A., Milhavet, O., Umlauf, D., Harris, D. and Lehmann, S. (2002) PrP-dependent cell adhesion in N2a neuroblastoma cells. Febs Letters 20 514,159-162). They showed that neuroblastoma cells overexpressing PrPc exhibit an increased aggregation behavior when compared to non-transfected cells. Addition of copper chelators or cation chelators during the cell aggregation assay had no significant effect, indicating that PrPc-mediated adhesion occurs in a cation-independent manner. Treatment of neuroblastoma cells with a polyclonal 25 antibody P45-66 that was raised against a synthetic peptide encompassing residues 45-66 of murine PrP (Lehmann, S. and Harris, D.A. (1995) A mutant prion protein displays an aberrant membrane association when expressed in cultured cells. J Biol Chem 270, 24589-24597) significantly inhibited cell aggregation. From these results it was concluded that PrP0 could function as an adhesion 30 molecule in neuronal cells, with cell aggregation being mediated by specific tran-scellular binding of PrPc to a heterologous protein such as N-CAM or laminin re
ceptor precursor. However, based on our finding that the OPR constitute a pH-dependent aggregation site, it appears also possible that PrPc is involved in homophiiic cell-cell recognition. This is consistent with aggregation suppressing activity of the antibody P45-66 whose epitope comprises the His containing OPR 5 that are responsible for pH-dependent PrP aggregation (Figure 1). The linear combination of two GPI anchored PrPc molecules in adjacent cells interact through an aggregation site in the OPR within an otherwise largely unstructured N-terminal domain would easily span the 20-30 nm distance of the synaptic cleft (Agnati, L.F., Zoli, M., Stromberg, I. and Fuxe, K. (1995) Intercellular Communi-10 cation in the Brain - Wiring Versus Volume Transmission. Neuroscience 69, 711-726). It is thus conceivable that prion proteins are similar to other homophiiic cell adhesion molecules such as the cadherins (Pokutta, S. and Weis, W.I. (2002) The cytoplasmic face of cell contact sites. Current Opinion in Structural Biology 12, 255-262), which are critically important for establishing brain structure and 15 connectivity during early development. Moreover, PrPc could participate in remodeling synaptic architecture and modifying the strength of the synaptic signal, thus playing an active role in synaptic structure, function, and plasticity. Because the cellular aggregation activity of PrPc does not depend on copper, the role of copper might be that of a chaperone allowing PrPc to switch between two oli-20 gomeric conformations with independent cellular functions, i.e. from copper-independent cell-cell adhesion to copper-dependent endocytosis and vice versa.
MATERIALS AND METHODS
1. Sample Preparation:
Cloning, expression and purification of hPrP polypeptides in unlabeled form or with uniform 1SN-Iabeling was achieved as previously described (Zahn, R., von Schroetter, C. and Wuthrich, K. (1997) Human prion proteins expressed in Es~ 30 cherichia coli and purified by high-affinity column refolding. FEBS Lett 417, 400-
404). Protein solutions were concentrated using Ultrafree-15 Centrifugal Filter Devices (Millipore).
2. NMR Measurements and Structure Calculations:
The NMR measurements were performed on Bruker DRX500, DRX750 and DRX800 spectrometers equipped with four radio-frequency channels and triple resonance probeheads with shielded z-gradient coils, with unlabeled or 1SN-labeled samples of 1 mM protein solutions in 90% H20/10% D20 or 99.9% D20 10 and at 20 °C. For the collection of conformational constraints, a three-dimensional lsN-resolved [1H/1H]-NOESY spectrum in H20 was recorded at 800 MHz with a mixing time xm = 100 ms at 7* = 20 °C, 207(f"i) x 39(t2) x 1024(f3) complex points, ti,max(*H) = 23.0 ms, t2,max(15N) = 21.4 ms, f^max^H) = 114 ms, and this data set was zero-filled to 512 x 128 x 2048 points. Processing of the spectra 15 was performed with the program PROSA (Guntert, P., Dotsch, V., Wider, G. and Wuthrich, K. (1992) Processing of Multidimensional Nmr Data with the New Software Prosa. Journal of Biomolecular Nmr 2, 619-629). The 1H and 1SN chemical shifts have been calibrated relative to 2,2-dimethyi-2-siiapentane-5-sulfonate, sodium salt.
Steady-state 15N{1H}-NOEs were measured at 500 MHz following Farrow et al., (Farrow, N.A., Zhang, O.W., Formankay, J.D. and Kay, L.E. (1994) A Heteronu-clear Correlation Experiment for Simultaneous Determination of N-15 Longitudinal Decay and Chemical-Exchange Rates of Systems in Slow Equilibrium. Journal 25 of Biomolecular Nmr 4, 727-734) using a proton saturation period of 3 s by applying a cascade of 120-degree pulses in 5 ms intervals; ti,max(15N) = 117.4 ms, t2,max(1H) = 146.3 ms, time domain data size 250(ti) x 1024(t2) complex points.
NOE assignment was obtained using the CANDID software (Herrmann, T., Guntert, P. and Wuthrich, K. (2002) Protein NMR structure determination with automated NOE assignment using the new software CANDID and the torsion an
gle dynamics algorithm DYANA. Journal of Molecular Biology 319, 209-227) in combination with the structure calculation program DYANA (Guntert, P., Mumen-thaler, C. and Wuthrich, K. (1997) Torsion angle dynamics for NMR structure calculation with the new program DYANA. Journal of Molecular Biology 273, 283-5 298). CANDID and DYANA perform automated NOE-assignment and distance calibration of NOE intensities, removal of covalently fixed distance constraints, structure calculation with torsion angle dynamics, and automatic NOE upper distance limit violation analysis. As input for CANDID, a peak; list of the aforementioned NOESY spectrum was generated by interactive peak picking with the pro-10 gram XEASY (Bartels, C., Xia, T.H., Billeter, M., Guntert, P. and Wuthrich, K.
(1995) The Program Xeasy for Computer-Supported Nmr Spectral-Analysis of Biological Macromolecules. Journal of Biomolecular Nmr 6, 1-10) and automatic integration of the peak volumes with the program SPSCAN (Ralf Glaser, personal communication). The input for the calculations with CANDID and DYANA con-
tained the NOESY peak list and a chemical shift list from the sequence-specific resonance assignments. The calculation followed the standard protocol of 7 cycles of iterative NOE assignment and structure calculation (Herrmann et al., 2002). During the first six CANDID cycles, ambiguous distance constraints were used. For the final structure calculation, only NOE distance constraints were re-20 tained that corresponded to NOE cross peaks with unambiguous assignment after the sixth cycle of calculation. Stereospecific assignments were identified by comparison of upper distance limits with the structure resulting from the sixth CANDID cycle. The 20 conformers with the lowest final DYANA target function values were energy-minimized in a water shell with the program OPALp 25 (Luginbuhl, P., Guntert, P., Billeter, M. and Wuthrich, K. (1996) The new program OPAL for molecular dynamics simulations and energy refinements of biological macromolecules. Journal of Biomolecular Nmr 8, 136-146), using the AMBER force field. The program MOLMOL (Koradi, R., Billeter, M. and Wuthrich, K.
(1996) MOLMOL: A program for display and analysis of macromolecular struc-30 tures. Journal of Molecular Graphics 14, 51-55) was used to analyze the result
ing 20 energy-minimized conformers (Tables 1 and 2) and to prepare drawings of the structures.
3. Dynamic Light Scattering Experiments:
The dynamic light scattering measurement were performed at 20 °C using a Protein Solutions Ltd. model 801 dynamic light scattering instrument (Hertford, U.K.). The Instrument calculates the translational diffusion coefficient £>t of the molecules in the sample cell from the autocorrelation function of scattered light 10 intensity data. The hydrodynamic radius RH of the scattering particle is derived from Dt, using the Stokes-Einstein relationship: Dr = kBT/ 6m\Rn, where kB is the Boltzmann constant, Tthe absolute temperature in Kelvin, i\ the viscosity of the solvent. Protein concentration was 4 mg/ml in buffer solution containing 10 mM sodium acetate at pH 4.5, or 10 mM sodium phosphate at pH 7.0. Protein solu-15 tions were filtered through 100 nm pore-size filters (Whatman, U.K.). To reduce interference with bubbles or dust, 30 data points were analyzed per experiment using the DynaPro dynamic light scattering instrument control software from molecular research DYNAMICS (version 4.0). The hydrodynamic radius Rh was calculated from the regularization histogram method using the spheres model, from 20 which an apparent molecular weight was estimated according to a standard curve calibrated for known globular proteins.
Claims (12)
1. A method for the reversible aggregation and/or dissociation of polypeptides, comprising the step of oligomerising a polypeptide at a pH of 6.2 to 7.8 and/or dissociating a polypeptide aggregate at a pH of 4.5 to 5.5 in a fluid environment, wherein the polypeptide is characterized in that (i) the polypeptide comprises one or more peptide repeat structures derived from prion proteins; (ii) and that the protein oligomerizes in fluid at pH of 6.2 to 7.8 and dissociates into monomers at a pH of 4.5 to 5.5.
2. The method of claim 1, wherein the peptide repeat is an octapeptide, pseudooctapeptide, hexapeptide or pseudohexapeptide.
3. The method of claim 2, wherein the octapeptide has a sequence selected from the group consisting of PHGGGWGQ (human), PHGGSWGQ (mouse) and PHGGGWSQ (rat), or is a pseudooctapeptide derived from said sequences.
4. The method of claim 3, wherein the pseudooctapeptide is selected from the group consisting of PHGGGGWSQ (various species), and PHGGGSNWGQ (marsupial).
5. The method of claim 2, wherein the hexapeptide has a sequence selected from the group consisting of PHNPGY (chicken), PHNPSY, PHNPGY (turtle) or is a pseudohexapeptide derived from said sequences.
6. The method according to any one of claims 1 to 5, wherein each of the peptide repeats comprises an N-terminal loop conformation connected to a C-terminal /3-turn structure.
7. The method according to any one of claims 1 to 6, wherein the polypeptide comprises four identical octapeptides.
8. A method for the reversible aggregation and/or dissociation of polypeptides, substantially as hereinbefore described with reference to any one of the examples.
9. Use of a method according to any one of claims 1 to 8 for detecting human or animal prion proteins.
10. Use of a method according to any one of claims 1 to 8 for affinity purification and/or enrichment of said polypeptides.
11. Use of a method according to claim 9 or 10, wherein said polypeptide is immobilized on a solid phase. 635361-1 intellectual property office of n.z. 12 JAN 2007 r>p^f-n/cn 31
12. Use of a method according to any one of claims 1 to 8 for chemical and/or physical sensor technology. Eidgenoessische Technische Hochschule Zurich By the Attorneys for the Applicant SPRUSON & FERGUSON Per: y 635361-1 intellectual property office of n.2. 1 2 JAN 2007 DECEIVED
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/397,059 US20040192887A1 (en) | 2003-03-25 | 2003-03-25 | PH-dependent polypeptide aggregation and its use |
PCT/EP2004/003060 WO2004085464A2 (en) | 2003-03-25 | 2004-03-23 | Ph-dependent polypeptide aggregation and its use |
Publications (1)
Publication Number | Publication Date |
---|---|
NZ543111A true NZ543111A (en) | 2007-03-30 |
Family
ID=32988937
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NZ543111A NZ543111A (en) | 2003-03-25 | 2004-03-23 | Method and use for the reversible aggregation and/or dissociation of polypeptides (comprising peptide repeats derived from prion, such as hexa- or octa-peptides) using a pH dependency mechanism |
Country Status (11)
Country | Link |
---|---|
US (1) | US20040192887A1 (en) |
EP (1) | EP1606628B1 (en) |
JP (1) | JP4354956B2 (en) |
CN (1) | CN100595209C (en) |
AT (1) | ATE343794T1 (en) |
AU (1) | AU2004224157B2 (en) |
CA (1) | CA2519993C (en) |
DE (1) | DE602004002943T2 (en) |
ES (1) | ES2274439T3 (en) |
NZ (1) | NZ543111A (en) |
WO (1) | WO2004085464A2 (en) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2267496C2 (en) | 2004-01-15 | 2006-01-10 | Сергей Иванович Черныш | Anti-tumor and antiviral peptides |
WO2007048588A1 (en) * | 2005-10-28 | 2007-05-03 | Alicon Ag | Method for concentrating, purifying and removing prion protein |
EA009555B1 (en) * | 2005-11-30 | 2008-02-28 | Сергей Иванович Черныш | Peptide having immunomodulating activity and pharmaceutical composition |
EP2533048A4 (en) * | 2010-02-03 | 2013-08-21 | Prism Biolab Co Ltd | Compound capable of binding to naturally occurring denatured protein, and method for screening for the compound |
CN111171115B (en) * | 2020-01-06 | 2022-05-27 | 山东大学 | Method for controlling reversible assembly of polypeptide crystal by adjusting pH value |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5164295A (en) * | 1991-03-06 | 1992-11-17 | The Upjohn Company | Method for identifying amyloid protein-extracellular matrix protein affinity altering compounds |
JP4233604B2 (en) * | 1991-12-03 | 2009-03-04 | プロセリックス メディスンズ ディベロップメント リミテッド | Prion protein fragment |
US5521158A (en) * | 1992-10-08 | 1996-05-28 | Scios Nova Inc. | Pseudopeptide bradykinin receptor antagonists |
US5891641A (en) * | 1997-02-21 | 1999-04-06 | The Regents Of The University Of California | Assay for disease related conformation of a protein |
FR2801106B1 (en) * | 1999-11-12 | 2007-10-05 | Commissariat Energie Atomique | METHOD FOR DIAGNOSING AN ATNC STRAIN-INDUCED TEST IN A BIOLOGICAL SAMPLE AND ITS USE IN THE DIFFERENTIAL DIAGNOSIS OF DIFFERENT ATNC STRAINS |
JP2003530554A (en) * | 2000-04-05 | 2003-10-14 | ブイ.アイ.テクノロジーズ,インコーポレイテッド | Prion binding peptide ligands and methods of using the same |
AU2002310497A1 (en) * | 2001-06-20 | 2003-01-08 | Caprion Pharmaceuticals Inc. | Protein aggregation assays and uses thereof |
-
2003
- 2003-03-25 US US10/397,059 patent/US20040192887A1/en not_active Abandoned
-
2004
- 2004-03-23 CN CN200480007849A patent/CN100595209C/en not_active Expired - Fee Related
- 2004-03-23 CA CA2519993A patent/CA2519993C/en not_active Expired - Fee Related
- 2004-03-23 DE DE602004002943T patent/DE602004002943T2/en not_active Expired - Lifetime
- 2004-03-23 AT AT04722562T patent/ATE343794T1/en not_active IP Right Cessation
- 2004-03-23 NZ NZ543111A patent/NZ543111A/en not_active IP Right Cessation
- 2004-03-23 ES ES04722562T patent/ES2274439T3/en not_active Expired - Lifetime
- 2004-03-23 EP EP04722562A patent/EP1606628B1/en not_active Expired - Lifetime
- 2004-03-23 WO PCT/EP2004/003060 patent/WO2004085464A2/en active IP Right Grant
- 2004-03-23 JP JP2005518681A patent/JP4354956B2/en not_active Expired - Fee Related
- 2004-03-23 AU AU2004224157A patent/AU2004224157B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
ES2274439T3 (en) | 2007-05-16 |
DE602004002943T2 (en) | 2007-07-05 |
AU2004224157B2 (en) | 2007-02-08 |
AU2004224157A1 (en) | 2004-10-07 |
EP1606628A2 (en) | 2005-12-21 |
CA2519993C (en) | 2011-02-15 |
DE602004002943D1 (en) | 2006-12-07 |
ATE343794T1 (en) | 2006-11-15 |
WO2004085464A2 (en) | 2004-10-07 |
CN1764840A (en) | 2006-04-26 |
WO2004085464A3 (en) | 2004-11-11 |
CN100595209C (en) | 2010-03-24 |
CA2519993A1 (en) | 2004-10-07 |
US20040192887A1 (en) | 2004-09-30 |
JP2007523831A (en) | 2007-08-23 |
JP4354956B2 (en) | 2009-10-28 |
EP1606628B1 (en) | 2006-10-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zahn | The octapeptide repeats in mammalian prion protein constitute a pH-dependent folding and aggregation site | |
Coles et al. | The solution structure and dynamics of human neutrophil gelatinase-associated lipocalin | |
Crescenzi et al. | Solution structure of the Alzheimer amyloid β‐peptide (1–42) in an apolar microenvironment: Similarity with a virus fusion domain | |
Yamin et al. | Forcing nonamyloidogenic β-synuclein to fibrillate | |
Öz et al. | Three-dimensional structure and dynamics of a brain specific growth inhibitory factor: metallothionein-3 | |
Van Doorslaer et al. | Unraveling the Cu2+ binding sites in the C-terminal domain of the murine prion protein: a pulse EPR and ENDOR study | |
Blanch et al. | Raman optical activity demonstrates poly (L-proline) II helix in the N-terminal region of the ovine prion protein: implications for function and misfunction | |
Di Natale et al. | Membrane interactions and conformational preferences of human and avian prion N-terminal tandem repeats: the role of copper (II) ions, pH, and membrane mimicking environments | |
Davies et al. | Thermodynamic and voltammetric characterization of the metal binding to the prion protein: insights into pH dependence and redox chemistry | |
Xie et al. | Interaction with synphilin‐1 promotes inclusion formation of α‐synuclein: mechanistic insights and pathological implication | |
Davies et al. | Contribution of individual histidines to prion protein copper binding | |
AU2004224157B2 (en) | pH-dependent polypeptide aggregation and its use | |
Nielsen et al. | Structure− activity studies of conantokins as human N-methyl-d-aspartate receptor modulators | |
Tibell et al. | Characterization of the heparin-binding domain of human extracellular superoxide dismutase | |
Gaggelli et al. | Structural characterization of the intra-and inter-repeat copper binding modes within the N-terminal region of “prion related protein”(PrP-rel-2) of zebrafish | |
Xu et al. | Molecular insight into Cu2+-induced conformational transitions of amyloid β-protein from fast kinetic analysis and molecular dynamics simulations | |
Dodero et al. | Analyzing the solution state of protein structure, interactions, and ligands by spectroscopic methods | |
Avizonis et al. | Conformations and dynamics of the essential cysteinyl-cysteine ring derived from the acetylcholine receptor | |
Pittman et al. | Nanodroplet Oligomers (NanDOs) of Aβ40: Published as part of the Biochemistry virtual special issue “Protein Condensates” | |
Pietropaolo et al. | Unveiling the role of histidine and tyrosine residues on the conformation of the avian prion hexarepeat domain | |
Leliveld et al. | Expansion of the octarepeat domain alters the misfolding pathway but not the folding pathway of the prion protein | |
Sakaguchi et al. | The effects of Cu2+ on conformational changes of hPrP180-192 derived from the C-terminal region of prion protein | |
Pedretti et al. | Role of myristoylation in modulating PCaP1 interaction with calmodulin | |
Rehders et al. | Peptide NMHRYPNQ of the Cellular Prion Protein (PrPC) Inhibits Aggregation and Is a Potential Key for Understanding Prion–Prion Interactions | |
Glaves et al. | Residue-specific mobility changes in soluble oligomers of the prion protein define regions involved in aggregation |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PSEA | Patent sealed | ||
RENW | Renewal (renewal fees accepted) | ||
RENW | Renewal (renewal fees accepted) | ||
LAPS | Patent lapsed |